Clinical Trials and Research

AbstractTransthyretin amyloidosis (ATTR) is a rapidly evolving disease with a rising prevalence and improving prognosis. With an increasing number of patients…

Study OverviewBrief SummaryThe goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA…

Background Hereditary transthyretin amyloidosis (hATTR) manifests as cardiomyopathy and/or polyneuropathy. The V142I variant predominantly causes cardiac disease in…

Long-term use of approved therapy safely extends patient survival, data showStarting Attruby (acoramidis) early and taking it continuously helps adults with…

A new study demonstrated that naturally occurring antibodies targeting transthyretin (TTR) are present in the serum of both healthy individuals and patients with…

Introduction: Cardiac amyloidosis is an infiltrative cardiomyopathy with high morbidity and mortality, frequently presenting as heart failure (HF) with preserved…

Transthyretin (ATTR) amyloidosis is a progressive systemic disease associated with substantial morbidity and mortality. Although health-related quality of life (…

The Amyloidosis Research Consortium’s Executive Director of Research, Kristen Hsu, discussed the current clinical trial landscape in AL amyloidosis. She reviewed…

Hereditary transthyretin amyloidosis (ATTRv) is a genetic disorder caused by more than 100 autosomal dominant mutations in the TTR gene. Owing to its marked…

Treatment shown to ease symptoms, reduce disability, improve quality of lifeAmvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability,…